Clinical Trial Update: Saxenda: Underlying Mechanisms and Clinical Outcomes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Saxenda (liraglutide) for obesity, detailing underlying mechanisms and clinical outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• SAXENDA (liraglutide)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Obesity | Phase 4 | Status: ACTIVE_NOT_RECRUITING